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Background. In 2014, the Italian Consensus for Classification and Reporting of+yroid Cytology (ICCRTC) reviewed the previous
cytological classification proposed in 2007 including the subdivision of TIR 3 category into low risk (TIR 3A) and high risk (TIR
3B). In Italian literature, different rates of malignancy have been correlated to these subcategories.Objectives. +e aim of the study
is to present our experience on this subclassification for the assessment of the malignancy risk of indeterminate thyroid nodules.
We correlated the subdivision into TIR 3A and TIR 3B with the histological report by highlighting the rates of malignancy
detected in the two subcategories. On the one hand, we aimed to check if the groups are associated with a real and significant
difference risk of malignancy. On the other hand, we evaluated the use of this subdivision in the choice of the appropriate
treatment. Study Design. +is is a retrospective review of all the patients with an indeterminate nodule who underwent US-FNA
and had surgery at ASL Citta` di Torino between January 2005 and May 2018. Results. 150 patients have been analyzed for the
research; 62 (41.3%) had a malignant histological report. Rates of malignancy between TIR 3A (20.8%) and TIR 3B (60.3%) were
significantly different (p< 0.0001). +e subclassification had high sensitivity (75.8%; CI 63.3–85.8%) and NPV (79.3%; CI
68–87.8%) and low specificity (64.8%; CI 53.9–74.7%) and PPV (60.3; CI 48.5–71.2%). +e measurement of the accuracy
(AUC= 0.7) classified the test as “moderately accurate.” Conclusions. Obtained data show a great rate of false negative (20.8%) and
limited AUC (0.7). According to our logistic regression, we argue that the 2014 subclassification into TIR 3A and TIR 3B should be
considered for the choice of patient treatment, but at the same time, we believe that the association with other screening tests is
necessary to increase the accuracy in the future.
1. Introduction
+yroid cancer is the most frequent endocrinological
cancer, the 2.1% of all the diagnosis of cancer in the world
[1]. In 2016 in Italy, patients with thyroid cancer were
160,307 [2]. +e critical issue about the management of
thyroid nodule is to distinguish preoperatively benign from
malignant lesions (8–16%) [3] in order to make treatment
most individualized.
+yroid fine-needle aspiration (FNA) cytology is the
most accurate and cost-effective screening and diagnostic
tool used for distinguishing thyroid cancers [4]. Sensitivity
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of FNA cytology stands at 95% [4]. It improves preoperative
diagnostic process and reduces unnecessary surgeries.
+e limits of FNA are inadequate samples (5–10%), due
to insufficient cellularity, and indeterminate reports (20–
25%) [5, 6].
We must consider FNA cytology as a screening test.
Final diagnosis is made by histological exam because what
define malignancy is capsule or blood vessels invasion, not
evaluable with cytological exam [4, 7].
To make communication between cytopathologists and
physicians more efficient, in 2007, the Italian Societies of
Endocrinology (AIT, SIE, and AME) and the Society of
Pathology and Diagnostic Cytology (SIAPEC-IAP) created a
“5-tiered TIR system” to classify FNA report of thyroid
nodules [4].
In 2014, a team of experts of the abovementioned so-
cieties reviews the previous classification: nodules classified
as TIR 3 have been divided into two subcategories with
different risk of malignancy: TIR 3A (low risk) and TIR 3B
(high risk) [8]. +e 6-tiered system created in 2014 is rep-
resented in Table 1.
Analyzing previous Italian studies, we observed dis-
crepancies in TIR 3A and TIR 3B malignancy rates: Uni-
versity La Sapienza of Roma reports a rate of 10.2% for TIR
3A nodules and 43.8% for TIR 3B (290 cases from 2008 to
2013) [9], University of Cagliari 21.1% for TIR 3A and 57.8%
for TIR 3B (102 cases from 2014 to 2016) [10], and ASL Citta`
di Torino 20.4% in TIR 3A and 53.8% in TIR 3B (96 cases
from 2005 to 2015) [11].
Trimboli et al. [6] performed a meta-analysis of online
articles until May 2018. +e incidence of malignancy among
the pooled series was 17% in TIR 3A category and 47% in
TIR 3B.
Due to these different rates, we decided to analyze and
present our experience.
2. Materials and Methods
2.1.DataCollection. +is is a retrospective review of medical
records of all the consecutive patients who underwent fine-
needle aspiration cytology with ultrasound guide and thy-
roid surgery in a unique institution during a period of 13
years (from January 2005 to May 2018). A flow chart of the
selection process of thyroid nodules is shown in Figure 1.
All the patients had a cytology report of TIR 3A and TIR
3B nodule, according to ICCRTC classification. +e cyto-
logical and histological samples were analyzed by a unique
pathology team.
Microscopic slides reported before 2014 were reanalyzed
by the same team and subdivided into the two categories.
Patients operated from 2005 to 2013 were 74/150 (49.3%), 34
were classified as TIR 3A lesions (47.2% of all TIR 3A in our
study) and 40 as TIR 3B (51.3% of the TIR 3B).
Patients operated after 2014 were 76/150 (50.7%), 38 had
a TIR 3A cytology report (52.8% of all TIR 3A), and 38 had a
TIR 3B report (48.7% of all TIR 3B).
All FNAs were performed under ultrasound guide with a
21G needle. Slides adequacy was verified based on guideline
of Papanicolaou Society [12] or Goellner Group [13]. All the
samples were evaluated by our pathology team and reported
according to 2014 ICCRTC classification.
TIR 3A category is characterized by specimen with in-
creased cellularity and numerous microfollicular structures
with low amount of colloid. +is group also includes par-
tially compromised specimens (due to preparation artifacts),
with cytologic or architectural alterations that cannot be
included in TIR 2 category [8].
TIR 3B group is characterized by a high cellularity in a
monotonous and repetitive microfollicular/trabecular ar-
rangement, with scant colloid. +is subcategory also in-
cludes samples characterized by nuclear alterations
suggestive of papillary carcinoma, too mild or focal to be
included in TIR 4 category [8].
During samples analysis, pathologists were not aware of
histological diagnosis in order to minimize bias.
2.2. Indication for Surgery. Before 2014, surgery was rec-
ommended to all the patients with a TIR 3 nodule. After
2014, just TIR 3B underwent surgery as first-line treatment
[14]. In case of a TIR 3A nodule, we considered the presence
of compressive symptoms (throat tightness, difficulty
breathing, and swallowing), risk factors (familiarity, expo-
sure of the neck to ionizing radiation, and previous diagnosis
of thyroid cancer in contralateral lobe) and ultrasound
properties (solid hypoechoic nodule or solid hypoechoic
component of a partially cystic nodule with high suspicion
characteristics such as irregular margins, micro-
calcifications, taller than wide shape, rim calcifications with
small extrusive soft tissue component, and evidence of extra
thyroid extension) [15].
In low-risk group, histologic data are available just for
patients who underwent surgery treatment. For this reason,
the rate of malignancy assigned to TIR 3A group represents
only an estimation of the real risk.
In our study, 116 total thyroidectomies and 34 lo-
bectomies were realized. Lobectomy was proposed to
patients with ultrasound pattern not suggestive of ma-
lignancy, absence of compressive symptomatology, uni-
lateral nodular disease, and regular function of
contralateral lobe.
2.3. Statistical Analysis. Data were processed by Stata®software. To compare the malignancy rates in TIR 3A and 3B
categories, the chi-squared test was used.
A ROC (receiver-operating characteristics) curve was
created. We calculated the AUC (area under the curve) in
order to measure the performance of the subclassification.
Subsequently, we realized a univariate and multivariate
logistic regression analysis. By convention, it was fixed as
level of significance p at 0.05.
3. Results
From January 2005 to May 2018, 150 patients underwent
fine-needle aspiration cytology with a TIR 3A or 3B report
and had surgery at ASL Citta` di Torino.
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For each specimen, demographic (age and sex), and
clinical data (nodule size and serum preoperative TSH) were
obtained.
Patients were subdivided into TIR 3A and 3B category:
72 had a cytology report TIR 3A (48%) and 78 TIR 3B (52%).
62 patients (41.33%) had a final malignant histological re-
port, considered as the Gold Standard of the diagnosis of
thyroid carcinoma. In particular, we found 15 malignant
diseases in TIR 3A category (20.83%) and 47 in TIR 3B
(60.26%). Collected information of the analyzed population
is shown in Table 2 while Table 3 shows the final histological
diagnosis.
A 2× 2 contingency table was created to compare TIR 3A
and TIR 3B categories and calculate the main diagnostic
indicators. +e obtained values are shown in Table 4.
+e prevalence of malignancy in TIR 3A category was
20.83% (15/72), whereas in TIR 3B group, it was 60.26% (47/
78). +e difference was statistically significant (p< 0.0001).
+e two groups of patients (with and without cancer)
were not different according to age (52.22 vs. 53.02 years,
t � 0.3487), sex (p � 0.5032), nodule dimension (1.7 vs.
2.0 cm, p � 0.8212), preoperative serum TSH (1.333 vs.
1.989mU/L, p � 0.0556), intranodal vascularity (p � 0.681),
and type of surgery (p � 0.677).
Considering cytology categories (TIR 3A and TIR 3B),
there is no difference between the two groups according to
age (TIR 3A: 53.76 vs. TIR 3B: 51.71 years, t � 0.9162), sex
(p � 0.2829), or nodule dimension (TIR 3A: 2 vs. TIR 3B:
1.6 cm, p � 0.5825).
A logistic regression was performed to compare patients
with and without malignant histological diagnosis and to
evaluate the influence of clinical and demographic charac-
teristics on the final diagnosis. In our study, we considered
age, gender, preoperatory serum TSH, cytology, type of
surgery, and intranodal vascularity, as shown in Table 5.
In univariate model, cytology is the unique variable that
shows a significative influence on the histological report
(p< 0.0001).
As previous univariate model, in multivariate logistic
regression, cytology is the unique variable correlated to a
Table 1: Diagnostic categories, expected risk of malignancy, and suggested management in 2014 ICCRTC classification [14].
Diagnostic category Expected rate of malignancy(%) Recommendation
TIR1 Not diagnostic Undefined FNA repetition after at least one month
TIR1C Not diagnostic, cystic Low, based on clinical features Focused on clinical features and/or FNArepetition
TIR2 Not malignant/benign <3 Follow-up
TIR3A Indeterminate nodule with low risk ofmalignancy <10 Follow-up/FNA repetition
TIR3B Indeterminate nodule with high risk ofmalignancy 15–30 Surgery
TIR4 Suspicious of malignancy 60–80 Surgery/intraoperatory histology eventually
TIR5 Malignant 95 Surgery; further diagnostic exams if necessary
TIR 3B: surgical treatment
yroid nodule
Inclusion criteria for fine-needle aspiration cytology:
(i) Elevated serum TSH/cold nodule at scintigraphy
(ii) Dimension > 1cm or suspicion pattern [15] at
ultrasound 
TIR 3 report at fine-needle
aspiration cytology
Before 2014: all TIR 3 nodules
were sent to surgery
Aer 2014
Nodules without compressive symptoms, risk factors or high suspicion pattern at US:
ultrasound follow-up or FNA cytology repetition
Nodules with compressive symptoms (throat tightness, difficulty breathing and
swallowing), risk factors (familiarity, ionizing radiation, previous diagnosis of thyroid
cancer), or high suspicion pattern at US [15]: surgical treatment 
TIR 3A:
(i)
(ii)
Figure 1: Flowchart: selection process of TIR 3 nodule.
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significative influence on final histological diagnosis, as
shown in Table 6.
4. Discussion
Indeterminate lesions represent the 20–25% of cytological
reports of thyroid nodules [16].
It is a key issue to find an appropriate way to distinguish
benign from malignant disease.
In our institution, the difference between TIR 3A
(20.83%) and TIR 3B (60.26%) malignancy rates was sta-
tistically significant (p< 0.0001). Referring all patients with
TIR 3A cytology to surgery would lead to an overtreatment
in 4/5 of the patients, but it also means that 1/5 of the
patients, who had a low-risk cytology and a malignant final
diagnosis, could not be undertreated.
In our study, the malignancy rates are higher than the
ones shown in the 2014 ICCRTC guidelines (TIR 3A< 10%,
TIR 3B 15–30%) [8]. Our higher rates of malignancy in 3A
group could be related to a different way of selection for TIR
3A lesions: after 2014, 3A nodules were sent to surgical
treatment in case of compressive symptoms, risk factors, or
ultrasound properties.
We believe that rates of malignancy of TIR 3B group are
higher due to ameticulous selection of collection site (thanks
to the use of ultrasound guide for FNA cytology) and
anatomopathological analysis of the slides. Furthermore,
Nardi et al. specify that expected rate of malignancy for the
TIR 3 subcategories is mainly found on clinical experience
and is only partially based on the evidence of the published
data [8].
In our experience, the subclassification ICCRTC 2014
shows high sensitivity (75.8%) and negative predictive
value (79.2%), but limited specificity (64.7%) and positive
predictive value (60.3%). +e high negative predictive
value let detect a great number of benign lesions, but the
low specificity and positive predictive value carried a
significant number of false positive. +ese specimens are
especially adenomatous lesions (considered benign dis-
ease) classified as high-risk cytology. Histology is the only
way to differentiate correctly benign to malignant lesions
[8, 17].
In our study, we do not take into account the presence of
noninvasive follicular thyroid neoplasm with papillary-like
nuclear features (NIFTP). It is a borderline entity with in-
dolent clinical behavior [18]. As Trimboli et al. [6] under-
lined in their systematic review and meta-analysis,
considering NIFTP, a benign histological outcome could
decrease the rate of malignancy in both categories and the
odds ratio of TIR 3B against TIR 3A, reflecting a pre-
dominance of this kind of lesion in TIR 3B category.
+en, we elaborated a ROC curve (receiver operating
characteristic) and calculated the AUC (area under the
curve) as a measure of diagnostic accuracy (Figure 2).
Table 2: Demographic characteristics of the study population.
Cytology Total F M Mean age (years) Malignant lesions Mean dimension (cm)
TIR 3A 72 56 16 54 (25–79) 15 (20.83%) 2.65
TIR 3B 78 66 12 52 (22–84) 47 (60.26%) 2.23
Table 3: Final histological diagnosis associated with the relative cytological reports.
Histological diagnosis TIR 3A TIR 3B Total
Adenoma 23 20 43
Papillary carcinoma 9 27 36
Follicular carcinoma 6 19 25
Poorly differentiated carcinoma 0 1 1
Medullary carcinoma 0 1 1
Goiter 27 9 36
+yroiditis 7 1 8
Total 72 78 150
Malignant reports: follicular, papillary, poorly differentiated, oncocytic, and medullary carcinoma. Benign reports: adenoma, struma, and thyroiditis.
Table 4: Main diagnostic indicators of 2014 ICCRTC subclassification.
Sensitivity
(IC 95%)
Specificity
(CI 95%)
PPV
(CI 95%)
NPV
(CI 95%)
Likelihood ratio (+)
(CI 95%)
Likelihood ratio (− )
(CI 95%)
Odds ratio
(CI 95%)
Area under ROC
(CI 95%)
75.8
(63.3–85.8)
64.7
(53.9–74.7)
60.3
(48.5–71.2)
79.2
(68–87.8)
2.15
(1.57–2.95)
0.374
(0.234–0.596)
5.76
(2.8–11.9)
0.703
(0.629–0.776)
Table 5: Univariate logistic regression: analyzed variables and their
respective p value.
Analyzed variable (univariate logistic regression) p value
Age 0.726
Gender 0.504
Serum TSH 0.277
Cytology 0.0001
Type of surgery 0.677
Intranodal vascularity 0.681
Nodule dimension 0.388
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+e accuracy of 2014 ICCRTC subclassification (rep-
resented by line number 1 in the figure) differs from the
reference line (corresponding to a useless test and repre-
sented by line 2), but it does not reach the excellence (line 3).
In our analysis, the subclassification shows an accuracy of 0.7
that classified the test as “moderately accurate.” Considering
positive and negative likelihood ratios (LR (+)� 2.15; LR
(− )� 0.374), their values demonstrate a small impact on the
disease probability: the LR (+) shows an increase of ma-
lignancy probability of 15% in TIR 3B patients, while the LR
(− ) represents a reduction of the disease probability of 25%
in TIR 3A patients. +e test can be defined as “sometimes
useful.”
To analyze confounding factors, we considered age,
gender, preoperative TSH, nodule dimension, type of sur-
gery, and intranodal vascularity in benign and malignant
groups. No difference can be found between histology
groups.
In the logistic regression, a significant result is obtained
just for cytology (p< 0.0001). +e result has been confirmed
in the univariate and in the multivariate logistic regression
model. None of the other analyzed variables reach a sig-
nificative level (p> 0.05).
Although the logistic regression results and the different
malignancy rates of the cytology categories, we believe that
the association of further analysis is necessary in order to set
the real malignancy risk. For example, the use of immu-
nohistochemical markers can increase diagnostic accuracy
with clinical and economic benefits. Galectin-3 and HBME-
1 are the most commons markers used in thyroid FNA
specimens. +e association of both markers demonstrates
higher accuracy and sensitivity than the use of a single one
[19–21]. Although the results of these studies, immuno-
histochemical analysis are not used in clinical practice.
Another useful tool in the management of thyroid in-
determinate nodule could be the core needle biopsy (CNB).
Pyo et al. [22] affirm that the CNB has a higher conclusive
rate than the repetition of FNA cytology in nodule with
atypia of undetermined significance/follicular lesion of
undetermined significance (AUS/FLUS).
+e limits of our study are its retrospective nature and
the mixed analyzed population (made by patients treated
before and after 2014). TIR 3A group includes patients
surgically operated as a first-line treatment (from 2005 to
2013) and patients operated due to high-risk factors (from
2014 to 2018). +e last group represents the 52.8% of TIR 3A
patients (38/72). Because surgery indication of TIR 3A is not
based on cytological report, low-risk indeterminate nodules
treated after 2014 can be considered as a bias in the study.
Nevertheless, a trial with a surgical approach to all TIR 3A
patients is not ethical because of guidelines recommendation
and surgically risks correlated to the treatment.
5. Conclusion
+e aim of ICCRTC subclassification is to reduce unnecessary
surgeries rate without underestimate malignant diseases.
+e number of false negatives revealed by our study
cannot be ignored (20.8%): 1/5 of TIR 3A patients could
undergo an inappropriate treatment.
+e sensitivity (75.8%) and specificity (64.8%) of 2014
subclassification founded in our study show limited values.
Furthermore, diagnostic accuracy (represented by AUC)
defines the test as mildly accurate. Likelihood ratios (LR (+):
2.15 e LR (− ): 0.374) show a limited change in disease rates
for TIR 3B reports.
Nevertheless, multivariate logistic regressions show as
unique significative association the relation between cytol-
ogy and final histological exam.
For these reasons, the 2014 subclassification can be con-
sidered as a helpful tool in the diagnosis of intermediate
nodules, but we believe that the associationwith other screening
tests will be necessary to increase the accuracy in the future.
Despite the small case series setup in our study, we hope
our experience will be useful for a future improvement in the
diagnostic process of thyroid nodules.
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Figure 2: ROC curve of 2014 ICCRTC subclassification. (1) Ac-
curacy of 2014 ICCRTC subclassification. (2) Reference line,
corresponding to a useless test. (3) Excellent accuracy.
Table 6: Multivariate logistic regression model.
Malignancy Odds ratio Standard error z p CI 95%
Age 1.011098 0.0173889 0.64 0.521 0.977584–1.04576
Gender 1.788607 1.14382 0.91 0.363 0.5107035–6.264132
Dimension 1.183981 0.1845497 1.08 0.279 0.8723006–1.607028
Cytology 7.034768 3.568224 3.85 0.0001 2.603139–19.01088
Surgery 1.179955 0.6057121 0.32 0.747 0.4314333–3.227134
Intranodal vascularity 0.6030279 0.3193559 − 0.96 0.340 0.2135758–1.70264
_cons 0.0693466 0.087607 − 2.11 0.035 0.0058302–0.8248318
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